AT Bancorp raised its position in Merck & Co. (NYSE:MRK) by 0.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,601 shares of the company’s stock after buying an additional 22 shares during the period. AT Bancorp’s holdings in Merck & Co. were worth $611,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in MRK. Americafirst Capital Management LLC purchased a new stake in shares of Merck & Co. during the second quarter valued at $115,000. NewSquare Capital LLC raised its stake in shares of Merck & Co. by 14.2% in the second quarter. NewSquare Capital LLC now owns 2,104 shares of the company’s stock valued at $121,000 after buying an additional 261 shares during the period. First New York Securities LLC NY purchased a new stake in shares of Merck & Co. during the second quarter valued at $121,000. QCI Asset Management Inc. NY raised its stake in shares of Merck & Co. by 1.1% in the second quarter. QCI Asset Management Inc. NY now owns 2,382 shares of the company’s stock valued at $137,000 after buying an additional 27 shares during the period. Finally, Lowe fs LLC raised its stake in shares of Merck & Co. by 1.8% in the second quarter. Lowe fs LLC now owns 2,619 shares of the company’s stock valued at $151,000 after buying an additional 46 shares during the period. Institutional investors own 72.93% of the company’s stock.
Shares of Merck & Co. (NYSE:MRK) traded down 0.59% during mid-day trading on Friday, reaching $62.14. The company had a trading volume of 12,204,208 shares. Merck & Co. has a 12 month low of $47.97 and a 12 month high of $64.86. The firm’s 50-day moving average is $62.56 and its 200 day moving average is $58.70. The company has a market capitalization of $171.83 billion, a price-to-earnings ratio of 34.09 and a beta of 0.68.
Merck & Co. (NYSE:MRK) last released its quarterly earnings results on Friday, July 29th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.02. Merck & Co. had a return on equity of 23.41% and a net margin of 13.01%. The firm had revenue of $9.84 billion for the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter last year, the business posted $0.86 EPS. The company’s revenue for the quarter was up .6% on a year-over-year basis. On average, equities research analysts predict that Merck & Co. will post $3.75 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, October 7th. Shareholders of record on Thursday, September 15th were paid a $0.46 dividend. This represents a $1.84 annualized dividend and a dividend yield of 2.96%. The ex-dividend date was Tuesday, September 13th. Merck & Co.’s dividend payout ratio is 101.10%.
A number of equities research analysts have recently issued reports on MRK shares. Zacks Investment Research raised Merck & Co. from a “hold” rating to a “buy” rating and set a $70.00 target price on the stock in a research report on Friday. Bank of America Corp. raised Merck & Co. from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $57.00 to $70.00 in a research report on Thursday. Leerink Swann reaffirmed a “market perform” rating and set a $65.00 target price on shares of Merck & Co. in a research report on Wednesday. Barclays PLC reaffirmed an “overweight” rating on shares of Merck & Co. in a research report on Wednesday. Finally, Vetr lowered Merck & Co. from a “buy” rating to a “hold” rating and set a $64.84 target price on the stock. in a research report on Monday, October 10th. Twelve research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of €65.05 ($72.28).
In other Merck & Co. news, insider Weir Mirian M. Graddick sold 40,800 shares of Merck & Co. stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of €62.07 ($68.97), for a total value of €2,532,456.00 ($2,813,840.00). Following the sale, the insider now owns 128,973 shares of the company’s stock, valued at approximately €8,005,354.11 ($8,894,837.90). The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Adam H. Schechter sold 39,200 shares of Merck & Co. stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of €62.61 ($69.57), for a total value of €2,454,312.00 ($2,727,013.33). Following the completion of the sale, the executive vice president now directly owns 39,200 shares in the company, valued at approximately €2,454,312 ($2,727,013.33). The disclosure for this sale can be found here. 0.05% of the stock is owned by company insiders.
About Merck & Co.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.